A1C Almanac

Main Page

The Sardine Tin Every Woman on Statins Deserves

Posted

by

dr Karunia Valeriani Japar

Table of Contents
Category:
Tags: , , , , ,

Keywords: Statins, Sardines, Women’s Metabolic Health, DHA, Mitochondria, Food as Medicine

Statins, Women, and Metabolic Trade-Offs

Statins remain a cornerstone of atherosclerotic cardiovascular disease (ASCVD) prevention, with robust evidence for reducing myocardial infarction, stroke, and cardiovascular mortality in high‑risk populations. Their widespread use in an aging, metabolically vulnerable population has also brought an uncomfortable paradox into focus: while statins effectively lower low‑density lipoprotein (LDL) cholesterol, they modestly increase the risk of dysglycemia and new‑onset type 2 diabetes, particularly at higher doses and intensities. This trade‑off is especially salient in women, who already face under‑recognition of cardiometabolic disease, delayed diagnosis, and a historical lack of representation in cardiovascular outcome trials.

Emerging data suggest that statin‑associated metabolic side effects are not evenly distributed across sexes. Meta‑analyses and post‑hoc trial assessments indicate that female sex is a strong predictor of statin intolerance and that women exposed to statins may experience a disproportionately higher risk of new‑onset diabetes compared with men. Against this backdrop, a central question arises for clinicians working in longevity and preventive cardiometabolic care: rather than accepting this adverse‑effect profile as an inevitable cost of LDL lowering, can targeted nutritional strategies be deployed to mitigate statin‑related harm, particularly in women with existing metabolic vulnerability?

One provocative, food‑based candidate for such a strategy is hiding in plain sight on supermarket shelves: sardines. Sardines provide a dense matrix of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), together with calcium, vitamin D, vitamin B12, selenium, taurine, arginine, and other micronutrients with established relevance for cardiometabolic health, mitochondrial function, and glucose regulation. The working hypothesis of this article is that women on statins should, quite literally, be “prescribed” sardines, not a substitute for evidence-based pharmacotherapy, but as a low‑cost, high‑yield adjunct to offset key metabolic consequences of statin therapy and to support healthier aging trajectories.

Statins, Dysglyceima, and the “Sexist” Signal

Statin-Induced Dysglycemia: From Class Effect to Mechanism

Across randomized trials and large observational cohorts, statin therapy is consistently associated with a higher incidence of new‑onset diabetes. Meta‑analyses of placebo‑controlled randomized trials, including the large collaborative analysis by Sattar and colleagues, demonstrate approximately a 9% relative increase in incident type 2 diabetes with statin therapy compared with control over about four years of follow‑up. More intensive LDL‑cholesterol lowering with higher‑dose statins confers an even greater risk, with some pooled analyses reporting roughly an 18% increase in diabetes incidence relative to less intensive regimens. Observational studies conducted in routine clinical populations have reported hazard ratios or odds ratios for new‑onset diabetes ranging up to 1.9, particularly in settings of higher baseline metabolic risk and longer treatment duration, underscoring that the diabetogenic signal is not confined to trial conditions [1,2].

Mechanistic investigations help explain these epidemiological findings. Human and experimental work indicates that statins increase insulin resistance and modestly reduce insulin secretion, resulting in higher fasting glucose and an accelerated transition from prediabetes to overt diabetes in susceptible individuals. At the cellular level, interference with the mevalonate pathway alters isoprenoid synthesis and downstream signalling, affecting insulin receptor function, GLUT4 translocation, and beta‑cell survival. Mendelian randomization studies that use genetic variants in HMGCR, PCSK9, and LDLR to mimic long‑term LDL‑lowering suggest that intensified LDL receptor–mediated cholesterol reduction is intrinsically linked with higher diabetes risk, supporting the view that statin‑induced dysglycemia is, at least in part, an on‑target effect of the LDL‑lowering mechanism rather than a coincidental off‑target toxicity [1,3,4,5].

Why the Female Signal Matters

Historically, landmark statin outcome trials disproportionately enrolled middle‑aged men, leaving women underrepresented and limiting early insights into sex‑specific differences in efficacy and adverse effects. Subsequent cohort analyses have begun to fill this gap, revealing that women may bear a greater share of the metabolic cost of statin therapy. In the Women’s Health Initiative (WHI), which followed more than 150,000 postmenopausal women without diabetes at baseline, statin use was associated with a 71% higher unadjusted risk and a 48% higher adjusted risk of self‑reported new‑onset diabetes, with the signal appearing to be a class effect across different statins. Meta‑regression data further indicate that trials with a higher proportion of women tend to report greater rates of incident diabetes, suggesting that sex composition of study populations contributes meaningfully to the observed heterogeneity in diabetogenic risk [6,7,8].

Beyond dysglycemia, contemporary analyses have identified female sex as one of the strongest predictors of statin intolerance, including myalgias, fatigue, and muscle‑related symptoms that can impair adherence and attenuate long‑term cardiovascular benefit. Pharmacovigilance data from multi‑decade spontaneous reporting systems show that diabetes associated with statin therapy is reported at a significantly higher rate in women than in men, and this pattern holds across several widely used statins. Taken together, these findings suggest that women are not simply smaller versions of men in statin pharmacology; rather, sex‑specific biology meaningfully shapes both the benefit–risk profile and the lived experience of therapy [8].

Preclinical data now extend this sex‑specific vulnerability into mitochondrial biology and glucose regulation. In a recent Nature Communications study, statin-treated female mice, but not male mice, developed impaired  glucose tolerance, approximately  20% reductions in grip strength, reduced skeletal muscle mitochondrial respiration, and lower mitochondrial DNA content, accompanied by a roughly 40% depletion of the omega‑3 fatty acid docosahexaenoic acid (DHA) in the liver and muscle. Strikingly, these adverse effects in females were prevented by fish oil supplementation (as a source of DHA and EPA) or by reducing X‑chromosome dosage or expression of Kdm5c, a gene that escapes X‑inactivation and is expressed at higher levels in XX than XY animals [9].

Parallel human data showed that women exposed to short‑term high‑dose atorvastatin experienced more pronounced reductions in circulating DHA levels than men, and that decreases in DHA correlated with increases in fasting glucose. Induced pluripotent stem cell–derived myotubes from women who had developed statin‑associated diabetes exhibited impaired mitochondrial function when exposed to statins, whereas cells from men did not show the same degree of dysfunction. Collectively, these findings support a model in which “X chromosome dosage” modulates susceptibility to statin‑induced dysglycemia and mitochondrial impairment, with DHA depletion acting as a key mediator. In this framework, women and especially those with two X chromosomes can be viewed as the “canaries in the metabolic coal mine,” manifesting adverse statin effects earlier and more severely, and thereby signalling an opportunity for targeted preventive strategies such as DHA‑rich nutritional interventions [9].

DHA, Mitochondria, and the X Chromosome: Why Fatty Acids Matter for Statin Side Effects

Docosahexaenoic acid (DHA) is often described as a “brain fat,” but it functions far more broadly as a structural and signalling lipid that shapes membrane fluidity, receptor function, antioxidant capacity, and mitochondrial performance in multiple tissues, including skeletal muscle and pancreatic beta cells. Experimental work in rodents shows that enriching membranes with DHA improves skeletal muscle mitochondrial respiration, oxidative capacity, and exercise performance, consistent with its role in optimizing electron transport and limiting early age‑related declines in muscle function. In parallel, studies in cultured myotubes and in vivo models demonstrate that DHA incorporation into mitochondrial membranes can reduce oxidative stress and favour a more efficient bioenergetic profile, thereby supporting resilience under metabolic load [10,11,12,13].

Figure 1. Benefits of omega-3 fatty acid supplementation on protein metabolism and mitochondria function in skeletal function [13]

Both animal and human data now suggest that statin therapy can reduce circulating and tissue levels of DHA and, in some cases, other long‑chain n‑3 polyunsaturated fatty acids, with women exhibiting a more pronounced decline than men. In the Nature Communications study on statin adverse effects, female mice treated with statins developed impaired glucose tolerance, muscle weakness, reduced mitochondrial respiration, and lower mitochondrial DNA content, all in the context of roughly a 40% reduction in hepatic and muscular DHA levels. Importantly, fish oil supplementation, used as a source of DHA and EPA, prevented these adverse changes in female mice, supporting a causal link between DHA depletion and statin‑induced metabolic and mitochondrial dysfunction. In humans, short‑term atorvastatin therapy (40 mg daily for 10 weeks) significantly reduced plasma DHA levels in both sexes, but the absolute reduction was approximately twice as large in women as in men, and only women showed a concomitant rise in fasting glucose [9,13,14,15].

Mechanistically, reduced DHA enrichment of mitochondrial membranes can impair electron transport chain efficiency, increase electron leak and reactive oxygen species generation, and diminish overall bioenergetic capacity. These changes may synergize with statin‑induced decrements in coenzyme Q10, another key component of the electron transport chain, to amplify mitochondrial stress in skeletal muscle and other tissues. In beta cells, shifts in membrane fatty acid composition influence ion channel dynamics, exocytotic machinery, and vesicle fusion, providing a plausible link between statin‑associated DHA depletion and reductions in insulin secretion observed in some experimental and clinical studies. In this integrated view, DHA is not merely a passive structural component but an active determinant of how mitochondria and beta cells respond to the metabolic perturbation imposed by statins [3,4,5,12,13,16,17,18,19].

The “X chromosome dosage” hypothesis adds a genetic layer to this vulnerability. Several genes on the X chromosome escape X‑inactivation and are therefore expressed at higher levels in XX than XY individuals, including genes implicated in mitochondrial biogenesis, redox regulation, and lipid metabolism. In the statin‑DHA study by Zhang and colleagues, statin adverse effects such as dysglycemia, reduced mitochondrial respiration, impaired redox tone, and altered fatty acid gene expression, segregated not with gonadal sex but with X‑chromosome complement and dosage of the X‑linked gene Kdm5c. Female mice with a normal two‑allele complement of Kdm5c (xx, Kdm5c+/+) were susceptible to statin‑induced impairment of glucose tolerance, mitochondrial activity, and DHA depletion, whereas reducing Kdm5c dosage to a single allele (XX, Kdm5c+/-) mimicking the effective dosage in Kdm5c dosage to a single allele (XX, Kdm5c+/-), mimicking the effective dosage in XY males, largely prevented these adverse effects [9,20,21].

Translational data support the relevance of this mechanism in humans. Women receiving short‑term statin therapy experienced larger drops in DHA than men, and the degree of DHA reduction correlated inversely with fasting glucose levels. Moreover, induced pluripotent stem cell–derived myotubes from women who developed statin‑associated diabetes exhibited greater mitochondrial dysfunction upon statin exposure than myotubes from men, consistent with a sex‑ and X‑dosage‑linked susceptibility. Together, these findings suggest that X chromosome dosage and DHA status jointly influence the mitochondrial and glycemic responses to statins, helping explain why women may manifest a stronger adverse metabolic signal than men [9,14].

From a practical, preventive standpoint, this framework argues for a proactive approach to nutrient repletion and mitochondrial support in women on statins rather than waiting for myalgias, fatigue, or deteriorating glycemic control to emerge. Ensuring adequate intake of DHA‑rich foods or supplements becomes a rational co‑therapy aimed at stabilizing mitochondrial membranes, maintaining redox balance, and supporting beta‑cell function in the face of statin‑induced perturbation. Sardines stand out as a particularly compelling vehicle for this strategy: they deliver substantial amounts of DHA and EPA alongside selenium, vitamin D, B12, taurine, and other cofactors relevant to mitochondrial health and glucose homeostasis, in a whole‑food matrix that is accessible and cost‑effective. In women with an XX chromosomal complement on long‑term statin therapy, systematically incorporating such DHA‑dense foods can therefore be viewed as a targeted, mechanism‑informed attempt to buffer the X‑linked vulnerability of their mitochondria and metabolic systems [9,10,11,22,23].

Sardines as a Functional Food for Statin-Treated Women

Sardines are among the most nutrient‑dense animal foods per 100 g, delivering not only substantial amounts of EPA and DHA but also calcium, magnesium, phosphorus, potassium, selenium, iron, vitamin D, vitamin B12, niacin, taurine, and arginine in a whole‑food matrix. A 100‑g cooked portion provides around 382 mg of calcium (about 38% of the adult recommended intake), 2.9 mg of iron, 490 mg of phosphorus, and approximately 8.9 µg of vitamin B12, alongside appreciable amounts of vitamin D and magnesium, all of which support bone integrity, red blood cell production, and cardiovascular function. Compared with other commonly consumed fish, sardines are distinctive for their combination of high omega‑3 content and biologically active calcium (from the small, edible bones), as well as rich supplies of vitamin D, selenium, and B vitamins [24,25,26,27,28].

This nutrient constellation aligns closely with statin‑relevant physiology. Long‑chain omega‑3 fatty acids (EPA/DHA) exert anti‑inflammatory and triglyceride‑lowering effects, improve endothelial function, and can enhance insulin‑stimulated oxidative and non‑oxidative glucose disposal, including in human and primate models. Calcium, vitamin D, and phosphorus together underpin skeletal health, particularly crucial for postmenopausal women while also contributing to myocardial contraction and broader cardiovascular signalling. Potassium and magnesium support blood pressure regulation, vascular tone, and electrical stability, thereby complementing statin‑driven cardiovascular risk reduction. Selenium supports glutathione peroxidase and other selenoenzymes involved in antioxidant defence and mitochondrial redox balance, potentially buffering oxidative stress in statin‑exposed muscle. Taurine and arginine, present in meaningful quantities, have been implicated in blood pressure modulation, endothelial nitric oxide production, lipid metabolism, and glucose homeostasis, offering further leverage on cardiometabolic pathways. Collectively, sardines function less as a single‑nutrient intervention and more as a multi‑nutrient package that maps remarkably well onto the liabilities of statin therapy in older, metabolically at‑risk women [22,24,25,26,27,29,30,31].

The omega‑3 index (O3I), defined as the proportion of EPA and DHA in erythrocyte membranes has emerged as an independent predictor of coronary heart disease and sudden cardiac death, with levels ≥8% associated with lower cardiovascular mortality and levels <4% linked to higher risk. Randomized controlled trials in older adults with prediabetes or type 2 diabetes show that sardine consumption can materially raise the omega‑3 index into a more favourable range. In a 12‑month trial of 152 adults aged ≥65 years with prediabetes, adding 200 g of canned sardines per week to a standard type 2 diabetes–prevention diet increased omega‑3 intake, raised vitamin D and taurine status, and shifted participants out of the “very high risk” range for developing diabetes according to FINDRISC scores, with concurrent improvements in triglycerides, HDL cholesterol, adiponectin, HOMA‑IR, and blood pressure. In drug‑naïve patients with type 2 diabetes, enriching a standard dietary prescription with 100 g of sardines five days per week for six months did not significantly change HbA1c but did improve lipid parameters, reduce HOMA‑IR, and alter erythrocyte membrane fatty acid composition toward higher omega‑3 content, consistent with an increase in omega‑3 index to ranges considered cardioprotective [26,30,31,32].

The magnitude of omega‑3 index improvement achieved with sardine‑enriched diets in these studies is comparable to that seen with low‑dose fish oil or salmon interventions, yet it is accomplished without adding pills to the regimen of patients who are often already managing multiple medications, including statins, antihypertensives, and glucose‑lowering agents. For women on statins, whose risk of dysglycemia and myopathy may be partly mediated by DHA depletion and mitochondrial stress, using sardines to raise the omega‑3 index represents a physiologically coherent, food‑first strategy: it restores DHA and EPA in cell membranes, supplies co‑factors for mitochondrial and vascular health, and does so in a format that is affordable, widely available, and generally low in contaminants such as mercury. In this light, sardines can reasonably be considered a functional food tailored to the specific vulnerabilities of statin‑treated women, rather than just another generic source of omega‑3 fats [26,27,29,31,32].

How Sardines Might Counter Statin Harms in Women

Mitochondrial Support and Myopathy

Statin‑associated myopathy is widely thought to involve disruption of mitochondrial bioenergetics, in part through inhibition of mevalonate‑dependent coenzyme Q10 (CoQ10) synthesis, with downstream impairment of respiratory chain function and ATP generation in skeletal muscle. Statins lower circulating and, in some studies, intramuscular CoQ10 levels, and high‑dose regimens have been associated with reduced mitochondrial respiration and exercise capacity in patients who develop statin‑related myopathic symptoms. While CoQ10 supplementation can improve muscle symptoms in a subset of patients and is considered reasonable given its low toxicity, trial results are mixed and do not fully resolve the broader landscape of mitochondrial stress, oxidative damage, and micronutrient imbalance induced by statins [33,34,35,36].

Sardines offer a complementary, food‑based approach to this problem by delivering DHA and EPA, selenium, taurine, magnesium, and other micronutrients that together support mitochondrial membrane integrity, antioxidant defenses, and calcium handling in muscle cells. DHA‑rich phospholipid membranes in skeletal muscle and mitochondria have been shown to enhance oxidative capacity, improve electron transport chain efficiency, and reduce reactive oxygen species generation, thereby increasing resilience to metabolic and mechanical stress. Selenium, abundant in sardines, is an essential cofactor for selenoenzymes such as glutathione peroxidases and thioredoxin reductases, which detoxify peroxides and limit lipid peroxidation within mitochondrial membranes, potentially mitigating oxidative damage that contributes to statin‑related myopathy. Taurine and magnesium, also present in meaningful amounts, further stabilize excitable membranes and modulate ion fluxes and calcium homeostasis, which are critical for muscle excitability, contraction, and fatigue resistance [11,12,13,25,26,28,30].

For women, who appear more prone to statin intolerance and muscle symptoms and who face age‑related declines in bone and muscle mass, this nutrient combination is particularly attractive. By simultaneously addressing multiple nodes in the mitochondrial stress network, membrane composition, redox balance, calcium handling, and contractile function, regular sardine intake provides a broad‑spectrum mitochondrial support that CoQ10 alone cannot offer. In the context of the emerging evidence that statin‑treated women experience greater DHA depletion and mitochondrial vulnerability than men, such a whole‑food strategy directly targets a plausible mechanistic driver of sex‑biased myopathy risk [8,9,14].

Glucose Regulation and Inflammation

Omega‑3 fatty acids derived from oily fish have consistently demonstrated benefits across several cardiometabolic domains, including significant reductions in fasting triglycerides, modest improvements in blood pressure, and attenuation of systemic inflammation in populations with diabetes and cardiovascular disease. Meta‑analyses and controlled trials show that EPA/DHA supplementation lowers triglyceride levels, can improve insulin sensitivity, and reduces pro‑inflammatory cytokines such as TNF‑α, IL‑1β, and CRP in overweight and type 2 diabetes patients. Sardines, as a concentrated food source of EPA/DHA, have been specifically associated with normalization of blood pressure, improvements in lipid profile (lower triglycerides and, in some studies, higher HDL‑C), and favourable shifts in adipokines such as adiponectin in older adults at high metabolic risk [26,30,31,32,37].

Randomized trials of sardine‑enriched diets in older individuals with prediabetes and type 2 diabetes provide proof‑of‑concept that this fish can beneficially modulate the very milieu in which statin‑induced dysglycemia tends to emerge. In a 12‑month prevention study in older adults with prediabetes, adding 200 g of canned sardines per week to a standard type 2 diabetes‑prevention diet increased taurine and omega‑3 intake, improved blood pressure and triglycerides, raised adiponectin, and shifted a substantial proportion of participants out of the highest FINDRISC risk category for developing diabetes. In patients with established type 2 diabetes, a sardine‑enriched diet (100 g, five days per week for six months) improved triglycerides, reduced HOMA‑IR, and altered erythrocyte fatty acid profiles toward higher omega‑3 content, consistent with enhanced insulin sensitivity and a more cardioprotective omega‑3 index [38,39,40].

Beyond omega‑3s, taurine and arginine in sardines contribute additional glycemic and vascular benefits. Taurine has been shown to support glucose homeostasis by modulating the expression of genes essential for glucose‑stimulated insulin secretion (including sulfonylurea receptor‑1, glucokinase, GLUT2, and PDX‑1) and by enhancing insulin‑stimulated tyrosine phosphorylation of the insulin receptor in skeletal muscle and liver, thereby improving peripheral insulin sensitivity. Experimental work also indicates that combinations of omega‑3 fatty acids and taurine produce greater cardioprotective and anti‑inflammatory effects than either nutrient alone, including reductions in glucose and insulin levels and improvements in leptin resistance in diabetic mouse models. Arginine serves as a substrate for endothelial nitric oxide synthase, promoting nitric oxide–mediated vasodilation, improved endothelial function, and potentially better skeletal muscle glucose uptake via enhanced blood flow and microvascular recruitment [26,30,38].

Clinically, many statin‑treated patients who go on to develop diabetes present with preexisting prediabetes, central obesity, hypertension, dyslipidemia, and low‑grade inflammation, the classic phenotype of metabolic syndrome. Integrating sardines into their regular diet directly targets this high‑risk terrain by lowering triglycerides, improving blood pressure, augmenting adiponectin, and supporting insulin signalling through multiple mechanisms. For women, who in cohorts such as the Women’s Health Initiative exhibit a disproportionately higher relative increase in diabetes risk on statins, a food‑anchored mitigation strategy centered on sardines is both biologically plausible and clinically congruent with preventive cardiometabolic care: it aligns with guideline recommendations to consume oily fish, addresses specific mechanistic vulnerabilities (DHA depletion, mitochondrial stress, inflammation, insulin resistance), and does so without adding to the pill burden already associated with long‑term statin therapy [4,7,26,29,30,31,41,42,43].

Practical Prescribing: How to “Write Sardines on a Statin Script

Translating Evidence into Food-Based Guidance

Although no randomized trial has yet compared “statins plus sardines” directly against “statins alone,” clinicians can reasonably extrapolate from sardine RCTs in cardiometabolic populations and from broader fish‑intake guidelines. The 12‑month Clinical Nutrition trial in older adults with prediabetes showed that adding 200 g of canned sardines per week (two tins) to a standard type 2 diabetes–prevention diet reduced calculated diabetes risk, improved triglycerides, blood pressure, adiponectin, and omega‑3 status compared with the control diet alone. These findings align with integrative reviews concluding that 1–2 sardine servings per week is a reasonable baseline target, consistent with cardiovascular guidelines recommending at least one to two oily fish meals weekly (≈150–175 g per serving) to lower risk of major cardiovascular events and mortality [26,30,31,44,45,46].

For higher‑risk individuals, including older women with prediabetes or type 2 diabetes already receiving statins, more intensive sardine prescriptions have demonstrated favorable shifts in cardiometabolic markers. In drug‑naïve patients with type 2 diabetes, enriching the standard diet with 100 g of sardines five days per week for six months improved triglycerides, reduced HOMA‑IR, and altered erythrocyte membrane fatty acid composition toward higher omega‑3 content, consistent with a more protective omega‑3 index. In practice, this evidence can be operationalized as a tiered recommendation: (1) baseline at least 1–2 palm‑sized portions (≈100 g) of sardines per week, preferably with bones and packed in water, olive oil, or tomato sauce; (2) therapeutic for women on statins with prediabetes, metabolic syndrome, or diabetes, 2–5 sardine meals per week for 3–6 months, with follow‑up assessment of lipid profile, blood pressure, and glycemic markers; and (3) adjunctive, combining dietary sardines with foundational lifestyle strategies (resistance training, adequate protein, sleep, stress management) and, when indicated, coenzyme Q10 supplementation for statin‑associated myopathy. This approach leverages sardines as a structured, prescribable food intervention rather than an informal suggestion [26,30,32].

Safety, Sustainability, and Mercury Concerns

From a toxicology and sustainability standpoint, sardines are relatively low‑risk. As small, short‑lived, mid‑trophic fish, they accumulate far less mercury than large predatory species such as tuna, swordfish, or king mackerel, making them a safer long‑term choice for women across the menopausal transition and, by extension, for many individuals on chronic statin therapy. Their high selenium content further enhances safety by supporting selenoenzyme synthesis (e.g., glutathione peroxidases), which can mitigate mercury toxicity and oxidative stress within cardiovascular and nervous tissues. Large cohort analyses and pooled meta‑analyses indicate that fish consumption at levels of at least two servings per week is associated with reduced cardiovascular risk and that, at these intake levels, mercury‑related cardiovascular harm is not evident in the general or high‑risk populations studied [22,25,26,27,44,45,46].

The more practical barriers to “prescribing” sardines tend to be palatability, cultural norms, and gastrointestinal tolerance. These can often be addressed by culinary strategies, such as serving sardines with tomatoes, lemon, herbs, and extra‑virgin olive oil, or flaking them into salads, whole‑grain crackers, or vegetable‑rich dishes and by gradual dose titration from one serving weekly upward. For many women, especially those already managing complex medication regimens, the convenience, shelf‑stability, and low cost of tinned sardines make adherence more feasible than adding multiple separate supplements for omega‑3, calcium, vitamin D, and iron, while also preserving the synergistic benefits of the whole‑food nutrient matrix. In this sense, writing “sardines, 2–5 times per week” alongside a statin prescription is both a clinically pragmatic and an implementation‑friendly way to embed food‑as‑medicine into cardiometabolic and longevity care [26,31].

Limitations and Research Gaps

Despite strong mechanistic plausibility and supportive findings from sardine and omega‑3 interventions in cardiometabolic populations, there is currently no direct trial evidence that prescribing sardines specifically mitigates statin‑induced dysglycemia or myopathy in women. Most of the detailed mechanistic work linking DHA depletion, mitochondrial dysfunction, and X‑chromosome dosage to statin adverse effects has been conducted in animal models or in short‑term human studies focusing on biochemical and cellular endpoints, not on hard clinical outcomes such as incident diabetes or clinically adjudicated statin intolerance. Similarly, randomized controlled trials of sardine‑enriched diets have generally been small, of short‑ to medium‑term duration (months rather than years), and heterogeneous in design, with primary endpoints centered on lipids, blood pressure, inflammatory markers, FINDRISC scores, and omega‑3 index rather than conversion from prediabetes to diabetes or rates of statin discontinuation due to muscle symptoms.

A further limitation is that the nutrient doses achievable through realistic sardine consumption, especially for amino acids such as taurine and arginine, are lower than those used in supplementation trials that report clinically meaningful improvements in blood pressure and glycemic control. Taurine and arginine have shown antihypertensive and insulin‑sensitizing effects in animal models and in some human supplementation studies, but these typically employ gram‑level daily doses that exceed what can be obtained from a few weekly servings of sardines. Clinicians should therefore avoid over‑promising and instead position sardines as a supportive, not curative, component within a broader cardiometabolic risk‑reduction strategy that includes diet quality, physical activity, weight management, and pharmacotherapy where indicated. To validate the hypothesized benefit of “prescribing sardines” alongside statins, particularly in women with heightened metabolic vulnerability, large, adequately powered, sex‑stratified randomized trials are needed, with explicit testing of sardine‑based dietary patterns in statin‑treated patients and prespecified outcomes such as incident diabetes, changes in glycemic indices, myopathy rates, and treatment adherence [9,30,31].

Prescribing Sardines in a Statin World

For women, statins occupy a therapeutic space where substantial cardiovascular benefit coexists with a non‑trivial metabolic cost, and emerging evidence suggests that female sex and X‑chromosome dosage may amplify the risks of dysglycemia, mitochondrial dysfunction, and drug intolerance. Within this framework, the question of whether women on statins should be “prescribed” sardines becomes less whimsical and more a matter of rational mechanism‑informed preventive care. Sardines provide an unusually dense matrix of DHA, EPA, calcium, vitamin D, vitamin B12, selenium, taurine, arginine, and other nutrients that map closely onto both the recognized liabilities of statin therapy and the broader physiological needs of aging, metabolically vulnerable women.

Although definitive randomized trials directly testing sardine‑based interventions in statin‑treated women are still lacking, the convergence of mechanistic data, cardiometabolic nutrition studies, and omega‑3 index research supports a pragmatic, food‑first strategy. Routinely incorporating sardines into the diets of women on statins can be framed as a low‑risk, potentially high‑yield approach to enhancing omega‑3 status, supporting mitochondrial and muscle function, improving cardiometabolic biomarkers, and plausibly buffering against statin‑related adverse effects. In a longevity‑oriented clinical practice, the act of writing “sardines, 2–5 times per week” alongside a statin prescription is therefore more than a dietary embellishment; it reflects systems‑level thinking that integrates pharmacology with physiology and, crucially, centers the specific biological realities of women rather than treating them as an afterthought.

References

  1. Wang S, Cai R, Yuan Y, Varghese Z, Moorhead J, Ruan XZ. Association between reductions in low-density lipoprotein cholesterol with statin therapy and the risk of new-onset diabetes: a meta-analysis. Scientific Reports. 2017 Jan 10;7(1).
  2. Scientific Reports [Internet]. Scientific Reports. Available from: https://www.nature.com/srep/
  3. Abbasi F, Lamendola C, Harris CS, Harris V, Tsai MS, Tripathi P, et al. Statins Are Associated With Increased Insulin Resistance and Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology. 2021 Nov;41(11):2786–97.
  4. Rikhi R, Shapiro MD. Impact of Statin Therapy on Diabetes Incidence: Implications for Primary Prevention. Current Cardiology Reports. 2024 Sep 20;
  5. Laakso M, Lilian Fernandes Silva. Statins and risk of type 2 diabetes: Mechanism and clinical implications. Frontiers in Endocrinology [Internet]. 2023 Sep 19;14(1239335). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546337/#B11
  6. BJC [Internet]. Bjcardio.co.uk. 2012 [cited 2026 Mar 19]. Available from: https://bjcardio.co.uk/2012/03/statins-associated-with-increased-risk-of-diabetes/
  7. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin Use and Risk of Diabetes Mellitus in Postmenopausal Women in the Women’s Health Initiative. Archives of Internal Medicine [Internet]. 2012 Jan 23;172(2):144–52. Available from: https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/1108676
  8. Kao DP, Martin JL, Aquilante CL, Shalowitz EL, Leyba K, Kudron E, et al. Sex-differences in reporting of statin-associated diabetes mellitus to the US Food and Drug Administration. BMJ open diabetes research & care [Internet]. 2024 May;12(6):e004343. Available from: https://pubmed.ncbi.nlm.nih.gov/39638563/
  9. Zhang P, Munier JJ, Wiese CB, Vergnes L, Link JC, Abbasi F, et al. X chromosome dosage drives statin-induced dysglycemia and mitochondrial dysfunction. Nature communications [Internet]. 2024 Feb;15(1):5571. Available from: https://pubmed.ncbi.nlm.nih.gov/38956041/
  10. Banaszak M, Małgorzata Dobrzyńska, Kawka A, Górna I, Dagmara Woźniak, Juliusz Przysławski, et al. Role of Omega-3 fatty acids eicosapentaenoic (EPA) and docosahexaenoic (DHA) as modulatory and anti-inflammatory agents in noncommunicable diet-related diseases – Reports from the last 10 years. Clinical Nutrition ESPEN. 2024 Oct 1;63:240–58.
  11. Gerling CJ, Mukai K, Chabowski A, Heigenhauser GJF, Holloway GP, Spriet LL, et al. Incorporation of Omega-3 Fatty Acids Into Human Skeletal Muscle Sarcolemmal and Mitochondrial Membranes Following 12 Weeks of Fish Oil Supplementation. Frontiers in Physiology. 2019 Mar 29;10.
  12. Marie Le Guen, Valérie Chaté, Hininger-Favier I, Laillet B, Morio B, Pieroni G, et al. A 9-wk docosahexaenoic acid-enriched supplementation improves endurance exercise capacity and skeletal muscle mitochondrial function in adult rats. American Journal of Physiology-endocrinology and Metabolism. 2016 Feb 1;310(3):E213–24.
  13. Hayden JE, Deane CS. Skeletal muscle protein turnover and mitochondrial responses to omega-3 fatty acid supplementation: an update. Current Opinion in Clinical Nutrition & Metabolic Care. 2026 Jan 6;29(2):136–40.
  14. Yagi S, Kondo D, Ise T, Fukuda D, Yamaguchi K, Tetsuzo Wakatsuki, et al. Association of Decreased Docosahexaenoic Acid Level After Statin Therapy and Low Eicosapentaenoic Acid Level with In-Stent Restenosis in Patients with Acute Coronary Syndrome. Journal of atherosclerosis and thrombosis [Internet]. 2019 Mar 1 [cited 2024 Apr 14];26(3):272–81. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402885/
  15. Norwitz N. Why Women on Statins Should Be Prescribed Sardines [Internet]. Substack.com. StayCurious Metabolism; 2026 [cited 2026 Mar 20]. Available from: https://staycuriousmetabolism.substack.com/p/the-x-factor-why-statins-hit-women
  16. US8951514B2 – Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels – Google Patents [Internet]. Google.com. 2012 [cited 2026 Mar 20]. Available from: https://patents.google.com/patent/US8951514B2/en
  17. Ahmad K, Manongi NJ, Rajapandian R, Moti Wala S, Al Edani EM, Samuel EA, et al. Effectiveness of Coenzyme Q10 Supplementation in Statin-Induced Myopathy: A Systematic Review. Cureus. 2024 Aug 31;
  18. Ji S, Bian C, Sun J, Li H, Kaneko G, Ji H. Docosahexaenoic acid (DHA) regulates mitochondrial quality control via MEK/ERK activation to promote myoblast-to-myotube formation in grass carp (Ctenopharyngodon idellus). Aquaculture [Internet]. 2024 May 23;591:741123. Available from: https://www.sciencedirect.com/science/article/abs/pii/S0044848624005842
  19. Qu H, Guo M, Chai H, Wang W, Gao Z, Shi D. Effects of Coenzyme Q10 on Statin‐Induced Myopathy: An Updated Meta‐Analysis of Randomized Controlled Trials. Journal of the American Heart Association. 2018 Oct 2;7(19).
  20. Lin H, Gupta V, VerMilyea MD, Falciani F, Lee JT, O’Neill LP, et al. Dosage Compensation in the Mouse Balances Up-Regulation and Silencing of X-Linked Genes. Reik W, editor. PLoS Biology. 2007 Dec 11;5(12):e326.
  21. Client Challenge [Internet]. Nature.com. 2026 [cited 2026 Mar 20]. Available from: https://www.nature.com/ncomms/articles?searchType=journalSearch&sort=PubDate&type=article&year=2024&page=253
  22. Gabrielius B. Sardines reduce the risks of cardiovascular diseases and help prevent the formation of blood clots, according to a Harvard study [Internet]. SARDINELE. 2024 [cited 2026 Mar 20]. Available from: https://sardinele.lt/en/blogs/articles/sardines-reduce-risk-of-heart-and-vascular-diseases-help-prevent-blood-clot-formation-reveals-harvard-study
  23. Djuricic I, Calder PC. Omega-3 (n-3) Fatty Acid–Statin Interaction: Evidence for a Novel Therapeutic Strategy for Atherosclerotic Cardiovascular Disease. Nutrients [Internet]. 2024 Jan 1;16(7):962. Available from: https://www.mdpi.com/2072-6643/16/7/962
  24. Vijay Kumar Malesu. News-Medical [Internet]. News-Medical. 2025. Available from: https://www.news-medical.net/health/Why-sardines-deserve-a-spot-on-your-plate-Surprising-health-benefits-of-this-tiny-fish.aspx
  25. Canned Sardine Nutrients [Internet]. Nutrivore. 2023 [cited 2026 Mar 20]. Available from: https://nutrivore.com/foods/canned-sardine-nutrients/
  26. Santos HO, May TL, Bueno AA. Eating more sardines instead of fish oil supplementation: Beyond omega-3 polyunsaturated fatty acids, a matrix of nutrients with cardiovascular benefits. Frontiers in Nutrition. 2023 Apr 14;10.
  27. Contributors WE. Are There Health Benefits to Eating Sardines? [Internet]. WebMD. 2024. Available from: https://www.webmd.com/diet/health-benefits-sardines
  28. Gabrielius B. Sardines are one of the most nutritious fish in the world! [Internet]. SARDINELE. 2024 [cited 2026 Mar 20]. Available from: https://sardinele.lt/en/blogs/articles/sardines-are-one-of-the-most-nutritious-foods-on-the-planet
  29. News-Medical. News-Medical [Internet]. News-Medical. 2021 [cited 2026 Mar 20]. Available from: https://www.news-medical.net/news/20210506/Regular-consumption-of-sardines-helps-prevent-the-onset-of-type-2-diabetes.aspx
  30. Díaz-Rizzolo DA, Miro A, Gomis R. Prevention of Type 2 Diabetes through Sardines Consumption: An Integrative Review. Food Reviews International. 2021 Jan 6;38(sup1):317–35.
  31. Sardines in the Diet Showed a Decrease in Type 2 Diabetes in the Elderly – Natural Health Research [Internet]. Natural Health Research – Where Science Supports Wellness. 2021 [cited 2026 Mar 20]. Available from: https://naturalhealthresearch.org/sardines-in-the-diet-showed-a-decrease-in-type-2-diabetes-in-the-elderly/
  32. Balfegó M, Canivell S, Hanzu FA, Sala-Vila A, Martínez-Medina M, Murillo S, et al. Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial. Lipids in Health and Disease [Internet]. 2016 Apr 18 [cited 2021 Sep 19];15:78. Available from: https://pubmed.ncbi.nlm.nih.gov/27090218/
  33. Deichmann R, Lavie C, Andrews S. Coenzyme Q10 and Statin-Induced Mitochondrial Dysfunction. The Ochsner Journal [Internet]. 2024;10(1):16. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC3096178/
  34. Zaleski AL, Taylor BA, Thompson PD. Coenzyme Q10 as Treatment for Statin-Associated Muscle Symptoms—A Good Idea, but…. Advances in Nutrition. 2018 Jul 1;9(4):519S523S.
  35. Zeeshan M, Raza A, Waseem A, Sadia, Mushtaq MR, Siddiqui S, et al. Association of Coenzyme Q10 Supplementation With Statin-Associated Muscle Symptoms in Long-Term Statin Users. Cureus. 2025 Sep 19;
  36. Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M, et al. Effects of statins on mitochondrial pathways. Journal of Cachexia, Sarcopenia and Muscle. 2021 Jan 29;12(2).
  37. Souza DR de, Pieri BL da S, Comim VH, Marques S de O, Luciano TF, Rodrigues MS, et al. Fish oil reduces subclinical inflammation, insulin resistance, and atherogenic factors in overweight/obese type 2 diabetes mellitus patients: A pre-post pilot study. Journal of Diabetes and its Complications. 2020 May;34(5):107553.
  38. Natto ZS, Yaghmoor W, Alshaeri HK, Van Dyke TE. Omega-3 Fatty Acids Effects on Inflammatory Biomarkers and Lipid Profiles among Diabetic and Cardiovascular Disease Patients: A Systematic Review and Meta-Analysis. Scientific Reports. 2019 Dec;9(1).
  39. McEwen B, Morel-Kopp MC, Tofler G, Ward C. Effect of Omega-3 Fish Oil on Cardiovascular Risk in Diabetes. The Diabetes Educator. 2010 Jun 9;36(4):565–84.
  40. Chauhan S. Role of omega-3 fatty acids on lipid profile in diabetic dyslipidaemia: Single blind, randomised clinical trial. JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. 2017;11(3).
  41. National Lipid Association. Guidelines for Lipid-Lowering in Women – What Have We Learned? | National Lipid Association Online [Internet]. Lipid.org. 2019 [cited 2026 Mar 20]. Available from: https://www.lipid.org/lipid-spin/fall-2019/guidelines-lipid-lowering-women-–-what-have-we-learned
  42. Aiman U, Najmi A, Khan RA. Statin induced diabetes and its clinical implications. Journal of Pharmacology & Pharmacotherapeutics [Internet]. 2014;5(3):181–5. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156828/
  43. Hoogwerf BJ. Statins may increase diabetes, but benefit still outweighs risk. Cleveland Clinic Journal of Medicine. 2023 Jan;90(1):53–62.
  44. Ricci H, Gaeta M, Franchi C, Poli A, Battino M, Dolci A, et al. Fish Intake in Relation to Fatal and Non-Fatal Cardiovascular Risk: A Systematic Review and Meta-Analysis of Cohort Studies. Nutrients [Internet]. 2023 Jan 1;15(21):4539. Available from: https://www.mdpi.com/2072-6643/15/21/4539#:~:text=5.
  45. Mohan D, Mente A, Dehghan M, Rangarajan S, O’Donnell M, Hu W, et al. Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. JAMA Internal Medicine. 2021 May 1;181(5):631.
  46. Fish: Friend or Foe? [Internet]. The Nutrition Source. 2012. Available from: https://nutritionsource.hsph.harvard.edu/fish/

Discover more from A1C Almanac

Subscribe now to keep reading and get access to the full archive.

Continue reading